Study Information
Status: Active, Not Recruiting
Study Details
View study details on clinicaltrials.gov.
Locations
Palo Alto/Santa Cruz
Clinical Trial FAQs
Information for patients and study volunteers, including frequently asked questions.
Description
A Multiple Sclerosis study to evaluate the efficacy and safety of fenebrutinib on disability progression in adult participants with Primary Progressive Multiple Sclerosis (PPMS). All eligible participants will be randomized 1:1 to either daily oral fenebrutinib (or placebo) or intravenous (IV) ocrelizumab (or placebo) in a blinded fashion. Approximately 946 participants will be enrolled and will be recruited globally.
Principal Investigator
Ariele L Greenfield, M.D., Director of PAMF Multiple Sclerosis Center
Co-Investigator(s)
David Gershfield, MD, Minal Bhanushali, MD, PAMFRI Medical Director, Christine Hessler, MD
Funder
F. Hoffman-La Roche Ltd
Related Studies
GXCA
Gene Expression of Cerebral Aneurysms // [EMC]
Investigator: Lawrence Dickinson, M.D
Using Electronic Health Records to Identify Gaps in Migraine Headache Care: A Step Towards Improving Patient Outcomes
Use EHRs and survey data to characterize migraineurs at Sutter Health by demographic, comorbidity, symptom, and care gap profiles, to see if tx needs are met.
Mindfulness and Migraine: A Randomized Controlled Trial
Conduct a randomized controlled feasibility trial of mindfulness-based stress reduction for patients with moderate-to-severe migraine headache.
Investigator: Sylvia Sudat, PhD
Genetics and Comorbidity of Migraine
Identify common genetic variants for migraine to determine whether there are single nucleotide polymorphisms associated with migraine.